Agenus Email Format
Biotechnology ResearchMassachusetts, United States51-200 Employees
Agenus is a biotechnology company focused on immuno-oncology, developing a broad pipeline of immunological agents to treat cancer and infectious diseases. It aims to broaden the patient populations that can benefit from cancer immunotherapy by pursuing combination strategies that leverage a wide repertoire of antibody therapeutics, as well as adoptive cell therapies and adjuvants. The company advances adoptive cell therapies through MiNK Therapeutics and adjuvants through SaponiQx, and is headquartered in Lexington, Massachusetts. In the biotechnology and immuno-oncology space, Agenus positions itself with a diversified portfolio rather than a single-product approach. In June 2026, the company indicated continued progress on its botensilimab and balstilimab combination (BOT/BAL) as a central program during its virtual annual meeting.